University Hospitals Leuven, Leuven, Belgium.
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Transpl Int. 2022 Jul 20;35:10465. doi: 10.3389/ti.2022.10465. eCollection 2022.
For the past decades, complement activation and complement-mediated destruction of allograft cells were considered to play a central role in anti-HLA antibody-mediated rejection (AMR) of kidney transplants. However, also complement-independent mechanisms are relevant in the downstream immune activation induced by donor-specific antibodies, such as Fc-gamma receptor (FcγR)-mediated direct cellular activation. This article reviews the literature regarding FcγR involvement in AMR, and the potential contribution of FcγR gene polymorphisms to the risk for antibody mediated rejection of kidney transplants. There is large heterogeneity between the studies, both in the definition of the clinical phenotypes and in the technical aspects. The study populations were generally quite small, except for two larger study cohorts, which obviates drawing firm conclusions regarding the associations between AMR and specific FcγR polymorphisms. Although FcγR are central in the pathophysiology of AMR, it remains difficult to identify genetic risk factors for AMR in the recipient's genome, independent of clinical risk factors, independent of the donor-recipient genetic mismatch, and in the presence of powerful immunosuppressive agents. There is a need for larger, multi-center studies with standardised methods and endpoints to identify potentially relevant FcγR gene polymorphisms that represent an increased risk for AMR after kidney transplantation.
在过去的几十年中,补体激活和补体介导的同种异体细胞破坏被认为在抗 HLA 抗体介导的肾移植排斥反应 (AMR) 中起核心作用。然而,在供体特异性抗体诱导的下游免疫激活中,也存在补体非依赖性机制,例如 Fcγ 受体 (FcγR) 介导的直接细胞激活。本文综述了关于 FcγR 参与 AMR 的文献,并探讨了 FcγR 基因多态性对肾移植抗体介导排斥反应风险的潜在贡献。这些研究在临床表型的定义和技术方面存在很大的异质性。研究人群通常较小,除了两个较大的研究队列,这排除了关于 AMR 与特定 FcγR 多态性之间的关联得出明确结论的可能性。尽管 FcγR 在 AMR 的病理生理学中起核心作用,但在接受者基因组中,独立于临床危险因素、独立于供体-受者遗传不匹配、并且在强大的免疫抑制药物存在的情况下,仍然难以确定 AMR 的遗传危险因素。需要进行更大的、多中心的研究,采用标准化的方法和终点,以确定潜在相关的 FcγR 基因多态性,这些多态性代表肾移植后 AMR 的风险增加。